Here’s why the Neuren Pharmaceuticals (ASX:NEU) share price is up 11%

We take a look at what the pharmaceutical company announced today

| More on:
Medical professionals cheering good news. pro medicus

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price has jumped into the green during afternoon trading on Friday.

Neuren shares are on the move after the company made a key announcement earlier today.

Let’s investigate further.

What did Neuren announce?

Neuren advised that the US Food and Drug Administration (FDA) has granted “orphan drug designation” to one of the company’s drug candidates.

For reference, the term “orphan drug” is a label given to a drug or treatment that has been developed for medical conditions that are so rare, it would be unprofitable to produce without assistance from either a sponsor or the government.

The orphan drug designation gives companies involved a special tax window of 7 years. It also gives them exclusivity over the rights to develop a cure for these kinds of rare conditions.

According to today’s announcement, the FDA granted the orphan status to Neuren’s drug candidate “NNZ-2591”, which is about to initiate Phase 2 clinical trials across a number of complex diseases.

NNZ-2591 was granted orphan drug status for the treatment of Prader-Willi syndrome. This is a neurodevelopmental disorder that causes issues with weight regulation, learning disabilities, growth hormone deficiencies, gastrointestinal issues, and difficulty controlling emotions, amid other signs and symptoms.

Neuren had previously demonstrated positive outcomes from studies of NNZ-2591 in mice.

Investors have favoured the news and are rewarding the company, pushing the Neuren Pharmaceuticals share price higher.

Neuren shares are now exchanging hands at $2.50 apiece, an 11.11% jump on the day.

What did management say?

Speaking on the announcement, Neuren CEO Jon Pilcher said:

We were excited by the strong pre-clinical efficacy of NNZ-2591, which clearly demonstrated the potential for the mechanism of action to have a positive impact on Prader-Willi syndrome. We are now delighted to receive Orphan Drug designation from the FDA following review of our rationale and data. This underpins the commercial opportunity and follows Orphan Drug designation already granted for PhelanMcDermid, Angelman and Pitt Hopkins syndromes.

Neuren Pharmaceuticals share price snapshot

The Neuren Pharmaceuticals share price has climbed 89% into the green this year to date. It has also gained 94% over the past 12 months.

These results have outpaced the S&P/ASX 200 index (ASX: XJO)’s return of about 25% over the past year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A man in his 30s holds his computer underneath and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Share Gainers

Guess which ASX All Ords shares are serving up 15% gains today

Tech shares continue to lead the way on Wednesday.

Read more »

rising asx share price in food and consumer staples sector represented by happy face made from cut up banana
Share Gainers

Why Domino’s, EML, Talga, and Woolworths shares are pushing higher

These ASX shares are pushing higher on Wednesday...

Read more »

A graph ablaze with fire going up, indicating a fired up and surged share price
Share Gainers

These 3 ASX 200 tech shares are on fire today

Tech shares are broadly outperforming today following a strong lead from the US NASDAQ.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Gainers

Why Regis Resources, Sayona, Woodside, and Xero shares are pushing higher

These ASX shares are on form on Tuesday...

Read more »

A GWR Group female employee in a hard hat and overalls with high visibility stripes sits at the wheel of a large mining vehicle with mining equipment in the background.
Resources Shares

Why has the Pilbara Minerals share price soared 57% in FY22?

How did the Pilbara Minerals share price perform in the financial year?

Read more »

A man with a scrappy beard and wearing dark sunglasses and a beanie head covering raises a fist in happy celebration as he sits at is computer in a home environment.
Technology Shares

How Brainchip shares gained 63% in a year when tech stocks nosedived

The computer hardware provider was once considered a meme stock. Is it fair dinkum now?

Read more »

A technical manufacturer checks his work in a high-tech lab with precision equipment in the background.
Share Gainers

Guess which ASX All Ords share soared 21% to an 8-year high on Monday

One ASX All Ordinaries share enjoyed a stellar start to the week.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Share Gainers

Why APM, Block, Breville, and Superloop shares are charging higher

These ASX shares are charging higher on Monday...

Read more »